MAKE WAY FOR THE FIRST ACTIVE HEMOSTATIC POWDER

MAKE WAY FOR THE FIRST ACTIVE HEMOSTATIC POWDER

11 OCTOBER 2017

Biom’up announces the success of its IPO,  raising close to €38.1 million on Euronext Paris 

-First initial public offering in the healthcare sector on the Euronext regulated market in Paris in the last 6 months

-Strong institutional demand in France as well as abroad, especially in the United States and the United Kingdom: o balanced representation between general investors and healthcare specialists o Top 10 investors represented nearly 80% of institutional demand, a strong confidence in the company’s fundamentals

– Significant over subscription enabling an upsized transaction under favourable conditions:

€38.1 million raisedfollowing the full exercise of the Extension Clause o Biom’Up could raise up to €43.9 million in the event the Overallotment Option is fully exercised

-Offering Price set at €10.5 per share at the midpoint of the IPO range

-Market capitalization of approximately €113 million

-Trading will begin on Friday October 13, 2017

Read more:

 

pr-11-10-17

ALL NEWS

Legal Information: HEMOBLAST™ Bellows - Implantable Medical device Class III for surgery reserved for use by qualified healthcare professionals, reimbursement depends on each country.
Read the instructions for use on the packaging carefully before use. CE0086: BSI - Manufacturer: Biom’up SA France.